免疫检查点抑制剂CTLA-4在实体肿瘤治疗中的临床应用

Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors

摘要: 近年来，免疫治疗成为实体肿瘤治疗的新方法，大量免疫制剂被开发并应用于临床，其中以免疫检查点抑制剂(immune checkpoint inhibitors，ICIs)应用最为广泛，为肿瘤治疗开启了新时代。而以细胞毒性T淋巴细胞相关蛋白4(cytotoxic T-lymphocyte-associated protein 4, CTLA-4)为代表的ICIs类药物丰富了肿瘤免疫治疗方法，开启了双免疫疗法的全新治疗模式。本文就CTLA-4在晚期实体肿瘤治疗中的临床应用进行综述，以期为肿瘤免疫治疗提供参考。

Abstract: In recent years, immunotherapy has become a new method for solid tumor treatment, and a large number of immune preparations have been developed and applied in clinical practice. Among them, immune checkpoint inhibitors (ICIs) are widely used, ushering in a new era for tumor treatment. In particular, cytotoxic T-lymphocyte-associated protein 4(CTLA-4), as a representative drug, enriches tumor immunotherapy methods and opens up a new treatment mode of dual immunotherapy. This article reviews the clinical application progress of CTLA-4 in the treatment of advanced solid tumors, with the hope of providing reference for immunotherapy of tumors.